Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response | Zendy

Herman Andrés Perroud | Zendy; Carlos M. Alasino | Zendy; María J. Rico | Zendy; Leandro E. Mainetti | Zendy; Francisco Queralt | Zendy; Stella Maris Pezzotto | Zendy; Viviana R. Rozados | Zendy; O. Graciela Scharovsky | Zendy

Open Access

Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response

Author(s) -

Herman Andrés Perroud,

Carlos M. Alasino,

María J. Rico,

Leandro E. Mainetti,

Francisco Queralt,

Stella Maris Pezzotto,

Viviana R. Rozados,

O. Graciela Scharovsky

Publication year - 2015

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-015-2947-9

Subject(s) - medicine , cyclophosphamide , capecitabine , chemotherapy , celecoxib , oncology , breast cancer , clinical endpoint , toxicity , metastatic breast cancer , cancer , clinical trial , gastroenterology , colorectal cancer

Preclinical results showing therapeutic effect and low toxicity of metronomic chemotherapy with cyclophosphamide (Cy) + celecoxib (Cel) for mammary tumors encouraged its translation to the clinic for treating advanced breast cancer patients (ABCP).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research